日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A heterozygous CEBPA mutation disrupting the bZIP domain in a RUNX1 and SRSF2 mutational background causes MDS disease progression.

在 RUNX1 和 SRSF2 突变背景下,杂合 CEBPA 突变破坏了 bZIP 结构域,导致 MDS 疾病进展

Almaghrabi Ruba, Alyahyawi Yara, Keane Peter, Mian Syed A, Habel Khadidja, Atkinson Amelia, Ward Carl, Bayley Rachel, Sargas Claudia, Menendez Pablo, Murphy George J, Sobahy Turki, Baghdadi Mohammed A, Flemban Arwa F, Kabrah Saeed M, Torres-Ruiz Raul, Papapetrou Eirini P, Akerman Ildem, Raghavan Manoj, Barragan Eva, Bonnet Dominique, Bonifer Constanze, Garcia Paloma

CACSV: a computational web-sever that provides classification for cancer somatic genetic variants from different tissues

CACSV:一个计算网络服务器,可提供来自不同组织的癌症体细胞遗传变异的分类。

AlKurabi, Nahla; AlGahtani, Ahad; Sobahy, Turki M

Clinically actionable cancer somatic variants (CACSV): a tumor interpreted dataset for analytical workflows

具有临床意义的癌症体细胞变异(CACSV):用于分析工作流程的肿瘤解读数据集

Sobahy, Turki M; Tashkandi, Ghassan; Bahussain, Donya; Al-Harbi, Raneem

SARS-COV-2 Triggers the Development of Class I and Class II HLA Antibodies in Recovered Convalescent Plasma Donors

SARS-CoV-2 可诱导康复血浆捐献者体内产生 I 类和 II 类 HLA 抗体

Dada, Ashraf; Elhassan, Khalid; Bawayan, Rayan Mohammed; Albishi, Ghadeer; Hefni, Lama; Bassi, Sawsan; Sobahy, Turki; Cupler, Edward; AlBaz, Nabeela; Wali, Ghassan; Alraddadi, Basem; Alshukairi, Abeer N

Biweekly cetuximab in combination with capecitabine and oxaliplatin (XELOX) or irinotecan (XELIRI) in the first-line and second-line treatment of patients with RAS wild-type metastatic colorectal cancer

每两周一次的西妥昔单抗联合卡培他滨和奥沙利铂(XELOX方案)或伊立替康(XELIRI方案)用于RAS野生型转移性结直肠癌患者的一线和二线治疗。

Zekri, Jamal; Baghdadi, Mohammed Abbas; Ibrahim, Refaei Belal; Meliti, Abdelrazak; Sobahy, Turki M